Dignitana AB Publishes Q3 2024 Interim Report
More progress in reimbursement
Financial highlights Q3 2024
- Net Sales amounted to 22.8 MSEK (22.2), an increase of 3 percent over the same quarter in 2023.
- Operating Result amounted to -0.7 MSEK (-3.2).
- Net Result after financial items amounted to -1.5 MSEK (-3.7).
- EBITDA for the third quarter is positive at 2.1 MSEK (0.7).
- Earnings per share were -0.02 SEK (-0.05).
- Cash Balance amounted to 4.4 MSEK (7.0).
- Average Daily Treatment Revenue (ADTR)* was 231 TSEK (237) in the quarter.
Business highlights during the period)
- In August Dignitana leadership and Board members completed several PDMR transactions. Dignitana CEO Fredrik Jonsson purchased 50,000 shares, Chairman of the Board of Directors Klas Arildsson purchased 50,000 shares, and Board member Fredrik Lindgren purchased 143,511 shares.
Business highlights after the period
- Dignitana Board member Fredrik Lindgren completed a PDMR transaction in October purchasing 1,500,000 shares.
- In October Dignitana expanded the company’s partnership with InfuSystem Holdings, Inc. to include field service support of DigniCap in U.S. chemotherapy infusion centers, providing rapid and enhanced support to customers.
- Later that month the American Medical Association (AMA) issued three new CPT® Category I codes for scalp cooling that will become effective January 2026. The issuance of these permanent elevated codes is a significant milestone for the company that will result in increased reimbursement for providers and improved financial access for patients.
- In November the US Centers for Medicare & Medicaid Services (CMS) published the OPPS Final Rule with a 40 percent increase in the average rate for CPT® 0662T over the 2024 amount, providing greater financial support for Medicare-eligible patients.
- University Hospital Schleswig-Holstein in Kiel, Germany (UKSH) purchased two DigniCap Delta devices and began offering scalp cooling to their patients in October.
- In November the The Aleris Oncology Clinic at Sabbatsberg Hospital, Stockholm expanded access to scalp cooling for patients in Sweden. Aleris purchased a DigniCap Delta device after completing a successful pilot evaluation of scalp cooling at Aleris Christinakliniken.
Key Figures
| DIGNITANA GROUP | Q3 2024 | Q3 2023 | Q1-Q3 2024 | Q1-Q3 2023 | FY 2023 |
|---|---|---|---|---|---|
| Net sales, TSEK | 22,849 | 22,219 | 65,858 | 64,797 | 86,063 |
| Total revenues, TSEK | 23,077 | 22,345 | 66,411 | 67,109 | 89,025 |
| Net profit after financial items, TSEK | -1,547 | -3,685 | -18,057 | -12,285 | -17,228 |
| Cash and bank balances, TSEK | 4,448 | 6,961 | 4,448 | 6,961 | 6,027 |
| Earnings per share before and after dilution, SEK | -0.02 | -0.05 | -0.24 | -0.17 | -0.25 |
| verage Daily Treatment revenue, TSEK | 231 | 237 | 231 | 240 | 239 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"Transformation is necessary, because only if we can create growth and profitability will we truly be able to live up to our purpose." – Fredrik Jonsson, CEO
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-11-2024 08:30 CET.
For More Information Contact
Fredrik Jonsson, CEO, fredrik.jonsson@dignitana.com +46 708766444
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
Tags: